Zoledronic acid-induced acute psychiatric disorder

Area of Science:

• Pharmacology
• Clinical Medicine
• Neuroscience

Background:

• Zoledronic acid is a bisphosphonate commonly prescribed for osteoporosis, hypercalcemia, Paget's disease, and malignant tumors.
• While acute-phase responses are common adverse effects, psychiatric disorders are infrequently reported.
• Osteoporosis management often involves bisphosphonate therapy, necessitating awareness of all potential side effects.

Purpose of the Study:

• To report a rare case of acute psychiatric disorder following zoledronic acid infusion.
• To emphasize the importance of monitoring for psychiatric adverse reactions in patients treated with zoledronic acid.
• To contribute to the understanding of the neuropsychiatric effects of bisphosphonate therapy.

Main Methods:

• A case study approach was employed.
• Detailed clinical observation and patient history were recorded.
• Literature review on adverse reactions to zoledronic acid was conducted.

Main Results:

• An osteoporotic patient developed an acute psychiatric disorder after the first intravenous infusion of zoledronic acid.
• The patient's psychiatric symptoms emerged shortly after the drug administration.
• This presentation represents a rare but significant adverse event associated with zoledronic acid.

Conclusions:

• Acute psychiatric disorder is a rare but possible adverse reaction to zoledronic acid.
• Clinicians should maintain vigilance for psychiatric symptoms in patients undergoing zoledronic acid treatment.
• Further research may be warranted to elucidate the mechanisms behind these rare neuropsychiatric effects.